文献速递前列腺增生与排尿功能障碍

米拉贝隆与维贝格龙作为老年女性膀胱过度活动症一线治疗的探索性随机比较

Exploratory Randomized Comparison of Mirabegron and Vibegron as First-line Therapy for Overactive Bladder in Elderly Women.
PubMed 文献 · Urology · 2025-11-13

一项前瞻性、单中心、随机、开放标签试验纳入131例70岁及以上绝经后女性OAB患者,比较米拉贝隆50mg与维贝格龙50mg每日一次治疗12周。主要终点OABSS变化组间调整差异为-0.24(95%CI -1.12至0.64;

要点

  • 米拉贝隆与维贝格龙治疗12周后OABSS改善组间无显著差异。
  • 两组治疗相关不良事件发生率分别为22%和32%(p=0.24),多为轻度。
  • 单中心设计且统计效能有限,需更大规模多中心试验验证。

核心结论

  • 在未接受过药物治疗的老年女性OAB患者中,米拉贝隆与维贝格龙治疗12周疗效和安全性相当。

研究设计与样本

  • 前瞻性、单中心、随机、开放标签试验,纳入131例70岁及以上绝经后OAB女性,米拉贝隆50mg组n=64,维贝格龙50mg组n=67,每日一次治疗12周(UMIN000038288)。

主要发现

  • 最小临床重要变化率维贝格龙组数值上更高但无统计学差异。
  • 治疗相关不良事件发生率米拉贝隆组22%、维贝格龙组32%(p=0.24),多为轻度(口干、便秘)。
  • 严重事件罕见且被认为与药物无关。

关键数值与推荐

  • 主要终点为基线至第12周OABSS总评分变化。
  • 次要终点包括IPSS、KHQ、MCIC(OABSS≥3分或KHQ≥5分下降)及安全性结局(TRAEs和PVR)。

临床怎么用

  • 研究结果可为老年女性OAB患者选择一线β3肾上腺素受体激动剂提供初步参考。
  • 需注意单中心设计和有限统计效能,结论需更大规模多中心试验确认。

局限性

  • 单中心设计。
  • 统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare mirabegron and vibegron as initial pharmacotherapy for overactive bladder (OAB) in elderly women. METHODS: We conducted a prospective, single-center, randomized, open-label trial including 131 postmenopausal women aged 70 years or older with OAB, allocated to mirabegron 50 mg (n = 64) or vibegron 50 mg (n = 67) once daily for 12 weeks (UMIN000038288). The primary endpoint was the change in total Overactive Bladder Symptom Score (OABSS) from baseline to week 12. Secondary endpoints included International Prostate Symptom Score (IPSS), King's Health Questionnaire (KHQ), minimal clinically important change (MCIC; OABSS ≥3-point or KHQ ≥5-point reduction), and safety outcomes including treatment-related adverse events (TRAEs) and postvoid residual (PVR). RESULTS: Baseline characteristics were similar between groups. Both treatments yielded significant within-group improvements. The adjusted between-group difference in OABSS change was -0.24 (95% CI, -1.12 to 0.64; p = .59). MCIC rates were numerically higher with vibegron but not statistically different. TRAEs occurred in 22% and 32% of patients receiving mirabegron and vibegron, respectively (p = .24); most were mild (dry mouth, constipation). Serious events were rare and not considered drug-related. CONCLUSION: Over 12 weeks, mirabegron and vibegron showed comparable efficacy and safety in pharmacotherapy-naïve elderly women with OAB. Given the single-center design and limited statistical power, these findings provide preliminary insights that may help guide the selection of first-line β3-adrenergic receptor agonists and highlight the need for larger multicenter trials.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sato H, Otsuka S, Okumura Y, et al. Exploratory Randomized Comparison of Mirabegron and Vibegron as First-line Therapy for Overactive Bladder in Elderly Women. Urology. 2025. PMID: 41241296. doi:10.1016/j.urology.2025.11.225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。